VYNE Therapeutics (VYNE) AI Stock Analysis

• Market Cap: $21.50M
• Dividend Yield: N/A
• Average Volume (3M): 919.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: 43.03%
• EPS Growth: 81.75%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 16,664,892
• 10 Day Avg. Volume: 2,239,023
• 30 Day Avg. Volume: 919,303
• PEG Ratio: <0.01
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.29
• Enterprise Value/Market Cap: -1.05
• Enterprise Value/Revenue: -10.87
• Enterprise Value/Gross Profit: -37.45
• Enterprise Value/Ebitda: 0.15
• 1Y Price Target: $4.13
• Price Target Upside: 186.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 50 Neutral
• Price Target: $1.50 ▲(4.17%Upside)

VYNE's overall stock score reflects significant financial challenges, including persistent losses and negative cash flow, which are major concerns. Technical analysis provides some support with positive momentum signals, but overall, the negative valuation metrics highlight the company's current struggles in achieving profitability.

Positive Factors

Efficacy in Psoriasis

All subjects receiving VYN202 showed improvements in key signs and symptoms of disease, including scalp psoriasis.

Safety and Efficacy

No patients experienced any serious side effects, and no patients had to discontinue or interrupt treatment because of any treatment-emergent side effects.

Vitiligo Treatment Advancements

Repibresib's previous Phase 1b results suggest greater efficacy at an earlier time point compared to the only approved vitiligo therapy, Opzelura.

Negative Factors

Clinical Hold

The FDA has placed a clinical hold on the Phase Ib study evaluating VYN202 due to testicular toxicity observed in dogs.

Study Suspension

The company has suspended all screening, enrollment, and dosing in the VYN202 study and is working with the FDA to resolve the hold.

VYNE Therapeutics Business Overview & Revenue Model

Company Description

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

How the Company Makes Money

VYNE Therapeutics generates revenue primarily through the commercialization of its dermatology products. The company earns money by selling its pharmaceutical treatments to healthcare providers, pharmacies, and distributors. Additionally, VYNE may engage in strategic partnerships or licensing agreements with other pharmaceutical companies to expand the market reach of its products, which can provide additional revenue streams through upfront payments, royalties, or milestone payments. The company's focus on research and development also positions it to potentially benefit from future product launches and innovations in its therapeutic areas.

VYNE Therapeutics Financial Statement Overview

Summary

VYNE Therapeutics is struggling financially with declining revenue, negative profitability margins, and ongoing cash flow issues. While the balance sheet shows low leverage, consistent losses and negative cash flow raise concerns about financial sustainability.

Income Statement

VYNE Therapeutics has shown a significant decline in revenue over recent years, with a steep drop from 2020 to 2024. The gross profit margin is positive, but the company is facing substantial operating losses as evidenced by negative EBIT and EBITDA margins. The net profit margin is also significantly negative, highlighting persistent unprofitability. These metrics indicate challenges in achieving revenue growth and controlling costs.

Balance Sheet

The company has maintained a healthy equity position with a low debt-to-equity ratio, suggesting limited leverage risk. However, there is a consistent decrease in stockholders' equity over the last few years. The equity ratio is relatively strong, indicating a stable asset base primarily funded by equity. Despite these strengths, profitability remains an issue.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash burn, which is a concern for sustainability. Free cash flow has been negative, with limited growth in free cash flow, suggesting cash management challenges. The company has relied on financing activities to supplement cash needs, which could pose future risks if access to capital markets becomes constrained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	605.00K	501.00K	424.00K	477.00K	14.76M	20.99M
Gross Profit	605.00K	501.00K	424.00K	477.00K	11.41M	19.60M
EBITDA	-44.45M	-43.63M	-29.26M	-34.22M	-38.94M	-251.09M
Net Income	-42.20M	-39.83M	-28.45M	-33.95M	-73.33M	-255.57M
Balance Sheet
Total Assets	56.42M	66.91M	97.69M	40.76M	67.05M	93.74M
Cash, Cash Equivalents and Short-Term Investments	50.27M	61.52M	93.25M	30.91M	42.25M	58.59M
Total Debt	63.00K	99.00K	214.00K	-349.00K	349.00K	34.78M
Total Liabilities	12.29M	14.82M	8.95M	9.56M	18.41M	56.25M
Stockholders Equity	44.13M	52.09M	88.73M	31.20M	48.64M	37.49M
Cash Flow
Free Cash Flow	-37.57M	-34.09M	-25.34M	-29.20M	-56.37M	-137.19M
Operating Cash Flow	-37.45M	-33.97M	-25.34M	-29.20M	-56.37M	-137.08M
Investing Cash Flow	46.77M	23.36M	-57.35M	15.67M	1.03M	89.11M
Financing Cash Flow	-224.00K	-141.00K	82.39M	1.65M	39.78M	61.81M

VYNE Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.44
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYNE, the sentiment is Positive. The current price of 1.44 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.19, and below the 200-day MA of 2.10, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 56.51 is Neutral, neither overbought nor oversold. The STOCH value of 33.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VYNE.

VYNE Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.49B	0.22	-61.87%	2.28%	16.62%	1.08%
PLUR	50 Neutral	$45.35M	―	-1205.58%	―	203.23%	13.57%
VYNE	50 Neutral	$21.50M	―	-66.15%	―	43.03%	81.75%
CLNN	48 Neutral	$34.76M	―	-1738.36%	―	-43.55%	69.81%
PYPD	41 Neutral	$34.95M	―	-853.05%	―	―	34.97%
DARE	40 Underperform	$21.24M	―	597.53%	―	88.13%	92.45%
NRSN	30 Underperform	$50.14M	―	-2880.11%	―	―	31.09%

VYNE Therapeutics Corporate Events

VYNE Therapeutics Sees Strong Shareholder Support for Growth

VYNE Therapeutics’ stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing shares available for issuance and adjusting share recycling policies. During the annual meeting, all five proposals, including director elections and executive compensation, were approved, indicating strong shareholder support and potential for strategic growth.